ICER: Final Evidence Report and Policy Recommendations on Tirzepatide Now Available

The Institute for Clinical and Economic Review (ICER) just released their final evidence report on the diabetes 2 drug terzepatide. ICER found adequate evidence that Eli Lilly’s drug improved symptoms but did not find it had benefits over injectable semaglutide. The institute also determined that its health-benefit price benchmark (HBPB) ranges between a yearly cost of $5,500-$5,700.

According to the non-profit, “ICER’s HBPBs are price ranges suggesting the highest US price a manufacturer should charge for a treatment, based on the amount of improvement in overall health patients receive from that treatment, when a higher price would cause disproportionately greater losses in health among other patients in the health system due to rising overall costs of health care and health insurance. In short, it is the top price range at which a health system can reward innovation and better health for patients without doing more harm than good.”

Read more by clicking here.

(Source: ICER, February 15^th, 2022)